Overview

Study of Repeated Administration of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus

Status:
Completed
Trial end date:
2019-02-05
Target enrollment:
Participant gender:
Summary
this study extension objective is to evaluate the safety and tolerability of a 200-mcg dose every 4 weeks for 24 weeks of IPP-201101 in patients with active systemic lupus erythematosus (SLE) who had participated in the main study IP-005.
Phase:
Phase 3
Details
Lead Sponsor:
ImmuPharma